Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in New York: - Maimonides Medical Center — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- The New York Hospital Medical Center of Queens — Flushing, New York
- Glens Falls Hospital — Glens Falls, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…
Sponsor: NRG Oncology
NCT ID: NCT07097142
Sites in New York: - Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Highland Hospital — Rochester, New York
- University of Rochester — Rochester, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvemen…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07000084
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
Phase 3 Recruiting Industry
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in c…
Sponsor: Eli Lilly and Company
NCT ID: NCT07218380
Sites in New York: - Columbia University Irving Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Weill Cornell Medical College — New York, New York
- Wilmot Cancer Institute — Rochester, New York
Phase 3 Recruiting Industry
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06510374
Sites in New York: - Albany Medical College — Albany, New York
- Great Lakes Physician PC d/b/a Western New York Urology Associates — Cheektowaga, New York
- AccuMed Research Associates — Garden City, New York
- Northwell Health -The Arthur Smith Institute for Urology — Lake Success, New York
- Veterans Affairs New York Harbor Healthcare System - Manhattan VA Medical Center — New York, New York
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06319820
Sites in New York: - Integrated Medical Professionals — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Associated Medical Professionals of Ny — Syracuse, New York
- SUNY Upstate Med Univ — Syracuse, New York
Phase 2, Phase 3 Recruiting Industry
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07106762
Sites in New York: - Local Institution - 0248 — Buffalo, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 3 Recruiting Industry
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and …
Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06545955
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Great Lakes Physician PC d/b/a Western new York Urology Associates — Cheektowaga, New York
- Northwell Health -The Arthur Smith Institute for Urology — Lake Success, New York
- James J. Peters VA Medical Center — The Bronx, New York
Phase 2, Phase 3 Recruiting Industry
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizu…
Sponsor: Daiichi Sankyo
NCT ID: NCT07129993
Sites in New York: - Research Site — New York, New York
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Gué…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06919965
Sites in New York: - Associated Medical Professionals — Syracuse, New York
Phase 3 Recruiting Academic/Other
The purpose of this study is to look at two standard surgical techniques used during a radical cystectomy and see whether they influence outcomes such as length of stay in the hospital and infections after surgery. This trial will evaluate…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06703476
Sites in New York: - Memorial Sloan Kettering Suffolk-Commack (Consent Only) — Commack, New York
- Memorial Sloan Kettering Westchester (Consent Only) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) — New York, New York
- Memorial Sloan Kettering Nassau (Consent Only) — Rockville Centre, New York
Phase 3 Recruiting Academic/Other
The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with other NCCN-re…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06929286
Sites in New York: - Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in New York: - New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- Maimonides Medical Center — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
Phase 2 Recruiting Industry
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04879329
Sites in New York: - MSK Commack — Commack, New York
- MSK Wesrchester — Harrison, New York
- Northwell Health — Lake Success, New York
- Memorial Sloan Kattering Cancer Centre- Investigational Drug Service Pharmacy — Long Island City, New York
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). — New York, New York
Phase 2 Recruiting NIH
This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy inc…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061964
Sites in New York: - The New York Hospital Medical Center of Queens — Flushing, New York
- NYP/Weill Cornell Medical Center — New York, New York
Phase 2 Recruiting NIH
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunothe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06770582
Sites in New York: - Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
Phase 2 Recruiting Industry
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Sponsor: CG Oncology, Inc.
NCT ID: NCT06567743
Sites in New York: - Integrated Medical Professionals, PLLC (Solaris) — New York, New York
- University of Rochester — Rochester, New York
- SUNY Upstate — Syracuse, New York
- Associated Medical Professionals of NY, PLLC (US Urology Partners) — Syracuse, New York
- Montefiore Medical Center — The Bronx, New York
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establis…
Sponsor: enGene, Inc.
NCT ID: NCT04752722
Sites in New York: - Albany Medical College — Albany, New York
- Mount Sinai Medical Center — New Haven, New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Associated Medical Professionals of NY, — Syracuse, New York
Phase 2 Recruiting Industry
TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101…
Sponsor: Protara Therapeutics
NCT ID: NCT05951179
Sites in New York: - AccuMed Research Associates — Garden City, New York
- University of Rochester, Department of Urology — Rochester, New York
- Montefiore Medical Center — The Bronx, New York
Phase 1, Phase 2 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissue…
Sponsor: Pfizer
NCT ID: NCT07421700
Sites in New York: - New York Oncology Hematology — Albany, New York
- New York Oncology Hematology — Clifton Park, New York
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in New York: - Columbia University — New York, New York
- Memorial Sloan Kettering — New York, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and pre…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05316155
Sites in New York: - Associated Medical Professionals — Syracuse, New York
Phase 2 Recruiting Industry
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Sponsor: Tyra Biosciences, Inc
NCT ID: NCT06995677
Sites in New York: - Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers — New York, New York
- The Bronx Veterans Medical Research Foundation, Inc. — The Bronx, New York
Phase 2 Recruiting Industry
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06833073
Sites in New York: - Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0111) — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in New York: - Memorial Sloan-Kettering Cancer Center — New York, New York